Literature DB >> 26702050

Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts.

Christopher A Drummond1, Michael C Hill1, Huilin Shi1, Xiaoming Fan1, Jeffrey X Xie1, Steven T Haller1, David J Kennedy1, Jiang Liu2, Michael R Garrett3, Zijian Xie4, Christopher J Cooper1, Joseph I Shapiro2, Jiang Tian5.   

Abstract

Chronic kidney disease (CKD) is accompanied by cardiac fibrosis, hypertrophy, and dysfunction, which are commonly referred to as uremic cardiomyopathy. Our previous studies found that Na/K-ATPase ligands or 5/6th partial nephrectomy (PNx) induces cardiac fibrosis in rats and mice. The current study used in vitro and in vivo models to explore novel roles for microRNA in this mechanism of cardiac fibrosis formation. To accomplish this, we performed microRNA profiling with RT-qPCR based arrays on cardiac tissue from rats subjected to marinobufagenin (MBG) infusion or PNx. The analysis showed that a series of fibrosis-related microRNAs were dysregulated. Among the dysregulated microRNAs, microRNA (miR)-29b-3p, which directly targets mRNA of collagen, was consistently reduced in both PNx and MBG-infused animals. In vitro experiments demonstrated that treatment of primary cultures of adult rat cardiac fibroblasts with Na/K-ATPase ligands induced significant increases in the fibrosis marker, collagen protein, and mRNA expression compared with controls, whereas miR-29b-3p expression decreased >50%. Transfection of miR-29b-3p mimics into cardiac fibroblasts inhibited cardiotonic steroids-induced collagen synthesis. Moreover, a specific Na/K-ATPase signaling antagonist, pNaKtide, prevented ouabain-induced increases in collagen synthesis and decreases in miR-29b-3p expression in these cells. In conclusion, these data are the first to indicate that signaling through Na/K-ATPase regulates miRNAs and specifically, miR-29b-3p expression both in vivo and in vitro. Additionally, these data indicate that miR-29b-3p expression plays an important role in the formation of cardiac fibrosis in CKD.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  Na/K-ATPase; cardiovascular disease; chronic kidney disease; fibrosis; microRNA (miRNA)

Mesh:

Substances:

Year:  2015        PMID: 26702050      PMCID: PMC4773889          DOI: 10.1152/physiolgenomics.00116.2015

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  53 in total

1.  Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay.

Authors:  Man Liang; Ting Cai; Jiang Tian; Weikai Qu; Zi-Jian Xie
Journal:  J Biol Chem       Date:  2006-05-12       Impact factor: 5.157

2.  Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients.

Authors:  Nicola Squillace; Elena Bresciani; Antonio Torsello; Alessandra Bandera; Francesca Sabbatini; Chiara Giovannetti; Giuseppe Giunta; Luca Rovati; Massimo Del Bene; Vittorio Locatelli; Andrea Gori
Journal:  J Antimicrob Chemother       Date:  2014-07-25       Impact factor: 5.790

3.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

Review 4.  Therapeutic use of microRNAs in myocardial diseases.

Authors:  Michael V G Latronico; Gianlugi Condorelli
Journal:  Curr Heart Fail Rep       Date:  2011-09

5.  Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease.

Authors:  Steven T Haller; Christopher A Drummond; Yanling Yan; Jiang Liu; Jiang Tian; Deepak Malhotra; Joseph I Shapiro
Journal:  Am J Hypertens       Date:  2013-09-06       Impact factor: 2.689

6.  MicroRNA-146a and -21 cooperate to regulate vascular smooth muscle cell proliferation via modulation of the Notch signaling pathway.

Authors:  Jian Cao; Kui Zhang; Jubing Zheng; Ran Dong
Journal:  Mol Med Rep       Date:  2014-12-17       Impact factor: 2.952

7.  MicroRNA mimicry blocks pulmonary fibrosis.

Authors:  Rusty L Montgomery; Guoying Yu; Paul A Latimer; Christianna Stack; Kathryn Robinson; Christina M Dalby; Naftali Kaminski; Eva van Rooij
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

8.  Canonical transforming growth factor-β signaling regulates disintegrin metalloprotease expression in experimental renal fibrosis via miR-29.

Authors:  Vasudev Ramdas; Martin McBride; Laura Denby; Andrew H Baker
Journal:  Am J Pathol       Date:  2013-10-06       Impact factor: 4.307

9.  Hypoxia Induces Mesenchymal Gene Expression in Renal Tubular Epithelial Cells: An in vitro Model of Kidney Transplant Fibrosis.

Authors:  Stephanie Zell; Roland Schmitt; Sandra Witting; Hans H Kreipe; Kais Hussein; Jan U Becker
Journal:  Nephron Extra       Date:  2013-06-06

Review 10.  Renal dysfunction in heart failure patients: what is the evidence?

Authors:  Heath E Saltzman; Kumar Sharma; Paul J Mather; Sharon Rubin; Suzanne Adams; David Joshua Whellan
Journal:  Heart Fail Rev       Date:  2007-03-29       Impact factor: 4.654

View more
  25 in total

1.  Proinflammatory Effects of Cardiotonic Steroids Mediated by NKA α-1 (Na+/K+-ATPase α-1)/Src Complex in Renal Epithelial Cells and Immune Cells.

Authors:  Fatimah K Khalaf; Prabhatchandra Dube; Andrew L Kleinhenz; Deepak Malhotra; Amira Gohara; Christopher A Drummond; Jiang Tian; Steven T Haller; Zijian Xie; David J Kennedy
Journal:  Hypertension       Date:  2019-05-28       Impact factor: 10.190

2.  Src-independent ERK signaling through the rat α3 isoform of Na/K-ATPase.

Authors:  Namrata Madan; Yunhui Xu; Qiming Duan; Moumita Banerjee; Isabel Larre; Sandrine V Pierre; Zijian Xie
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-30       Impact factor: 4.249

3.  LncRNA TUG1 contributes to cardiac hypertrophy via regulating miR-29b-3p.

Authors:  Xue Zou; Jialiang Wang; Li Tang; Qian Wen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-06-10       Impact factor: 2.416

4.  Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target.

Authors:  X Fan; J Xie; J Tian
Journal:  Cardiovasc Pharm Open Access       Date:  2017-01-31

5.  Garlic (Allium sativum) exhibits a cardioprotective effect in experimental chronic renal failure rat model by reducing oxidative stress and controlling cardiac Na+/K+-ATPase activity and Ca2+ levels.

Authors:  Asmaa M S Gomaa; Alaa T Abdelhafez; Hazem A Aamer
Journal:  Cell Stress Chaperones       Date:  2018-04-21       Impact factor: 3.667

6.  MicroRNA profiling in kidney disease: Plasma versus plasma-derived exosomes.

Authors:  Jeffrey X Xie; Xiaoming Fan; Christopher A Drummond; Reetam Majumder; Yanmei Xie; Tian Chen; Lijun Liu; Steven T Haller; Pamela S Brewster; Lance D Dworkin; Christopher J Cooper; Jiang Tian
Journal:  Gene       Date:  2017-06-03       Impact factor: 3.688

7.  MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis.

Authors:  Ting Xie; Jiurong Liang; Yan Geng; Ningshan Liu; Adrianne Kurkciyan; Vrishika Kulur; Dong Leng; Nan Deng; Zhenqiu Liu; Jianbo Song; Peter Chen; Paul W Noble; Dianhua Jiang
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

8.  Cigarette smoking causes epigenetic changes associated with cardiorenal fibrosis.

Authors:  Christopher A Drummond; Laura E Crotty Alexander; Steven T Haller; Xiaoming Fan; Jeffrey X Xie; David J Kennedy; Jiang Liu; Yanling Yan; Dawn-Alita Hernandez; Denzil P Mathew; Christopher J Cooper; Joseph I Shapiro; Jiang Tian
Journal:  Physiol Genomics       Date:  2016-10-27       Impact factor: 3.107

Review 9.  Role of the microRNA-29 family in myocardial fibrosis.

Authors:  Changyan Li; Nan Wang; Peng Rao; Limeiting Wang; Di Lu; Lin Sun
Journal:  J Physiol Biochem       Date:  2021-05-28       Impact factor: 4.158

10.  Biased Effect of Cardiotonic Steroids on Na/K-ATPase-Mediated Signal Transduction.

Authors:  Yunhui Xu; Pauline Marck; Minqi Huang; Jeffrey X Xie; Tong Wang; Joseph I Shapiro; Liquan Cai; Feng Feng; Zijian Xie
Journal:  Mol Pharmacol       Date:  2021-01-25       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.